USA flag logo/image

An Official Website of the United States Government

NON-INVASIVE SALIVARY ASSESSMENT OF PREDIABETES AND DIABETES

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
96005
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
DE020973
Solicitation Year:
N/A
Solicitation Topic Code:
NIDCR
Solicitation Number:
N/A
Small Business Information
DIABETOMICS, LLC
20000 NW Walker Rd. BEAVERTON, OR -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2010
Title: NON-INVASIVE SALIVARY ASSESSMENT OF PREDIABETES AND DIABETES
Agency: HHS
Contract: 1R43DE020973-01
Award Amount: $149,822.00
 

Abstract:

DESCRIPTION (provided by applicant): The twin epidemics of obesity and diabetes threaten to overwhelm healthcare systems in the U.S. and worldwide, with almost 29 million Americans currently having frank diabetes (predominantly type-2; T2DM) and an additio nal 68 million with prediabetes. There is increasing evidence that periodontal disease and diabetes are related, and this connection is supported by our discovery of salivary biomarkers of diabetes. A major challenge in dealing with the burden of diabetes is our inability to easily and conveniently detect diabetes and prediabetes in at-risk populations due to the lack of a non-invasive, point-of-care test. The current standards for glucose homeostasis determination, i.e., oral glucose tolerance test or hemo globin A1c, are expensive and requires hospital visits that are an issue for disadvantaged populations, contributing to the health disparities that plague diabetes testing, care, and prevention. The goal of the studies that comprise this Phase-I proposal i s to validate novel salivary biomarkers of diabetes and prediabetes. Planned Phase-II studies will assess the performance of a subset of biomarkers and will incorporate optimized analytes into an efficient device design in order to develop a rapid, non-inv asive, multi-analyte diagnostic test for accurate assessment of prediabetes or frank diabetes that is superior to existing glucose-based parameters. Successful development of salivary testing for diabetes will have a significant impact on the effective man agement of this critical public health crisis. The simplicity and non-invasive aspects of this approach will also be of benefit in the developing world. In addition to a potential direct impact on diabetes detection and monitoring, the introduction of sali vary biomarkers for diabetes will greatly expand the scope of salivary diagnostics. While there has been intense interest in saliva as a diagnostic fluid, the practical application of saliva to human disease to date has been limited to a few examples such as testing for HIV and drugs of abuse. We believe that the successful development of salivary diabetes testing as proposed in this application will increase the appreciation of the advantages of saliva as a diagnostic fluid and encourage the expansion of i ts use in clinical diagnostics. PUBLIC HEALTH RELEVANCE: The incidence of diabetes is reaching epidemic proportions in the US and the world at large, with projected massive increases in the number of individuals with additional serious complications such as heart, kidney, and eye disease and cognitive decline. Diabetes and periodontal disease are both chronic inflammatory illnesses, and there is a growing consensus that these two disorders are interrelated. Specifically, diabetes is a risk factor for severe gingivitis and periodontitis, and periodontitis is a risk factor for poor glycemic control and, possibly, diabetic complications. A significant problem is the lack of a simple, inexpensive, and convenient approach to detect persons with diabetes or prediabetes to direct them to suitable treatments to prevent or delay development of more serious disease. Based upon the evidence that oral disease and diabetes are related, we have previously discovered proteins in saliva that correlate with diabetes. T his project will determine the ability of these salivary proteins to accurately predict the presence of diabetes and prediabetes in a clinical validation study, and will provide the foundation for incorporation of a set of these proteins into a simple non- invasive test device that will be suitable for medical office, home, and field use.

Principal Investigator:

Srinivasa R. Nagalla
5036860138
NAGALLASR@DIABETOMICS.COM

Business Contact:

Srinivsa R. Nagalla
robertsct@diabetomics.com
Small Business Information at Submission:

DIABETOMICS, LLC
DIABETOMICS, LLC 20000 NW Walker Rd. BEAVERTON, OR 97006

EIN/Tax ID: 168067220
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No